The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutationsAnita Villani, Meredith S. Irwin, Scott Davidson et al.|Nature Cancer|2022Cited by 127
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Fariba Goodarzian et al.|Nature Medicine|2023Cited by 125
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human CellsJiil Chung, Cynthia Hawkins, Yosef E. Maruvka et al.|Cancer Discovery|2020Cited by 85
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Yimei Li et al.|Journal of Clinical Oncology|2022Cited by 42
Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory PapillomatosisCal Robinson, Paolo Campisi, Michael Hart-Matyas et al.|Annals of Otology Rhinology & Laryngology|2023Cited by 9